Life Sciences Product Development Needs More Creative Fundraising | Latham & Watkins LLP

The life sciences industry depended historically on public offerings for fundraising to support costs of developing therapeutic pharmaceutical and biologic products. The average cost of discovering and developing these products has risen to over $3 billion.

Originally published by Bloomberg Law – November 7, 2023.

Please see full publication below for more information.

Leave a Comment

Your email address will not be published. Required fields are marked *